Summary
In this episode of Melanoma Matters, James Larkin and Sapna Patel discuss the Keynote 716 trial, focusing on the treatment of stage 2 melanoma. They explore the implications of adjuvant therapies, the significance of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS), and the role of BRAF testing in managing stage 2 patients. The conversation highlights the challenges in treating early-stage melanoma and the need for accurate biomarkers to identify high-risk patients. The episode concludes with reflections on the findings of Keynote 716 and future directions in melanoma treatment.
Keywords
melanoma, Keynote 716, stage 2 melanoma, adjuvant treatment, BRAF testing, recurrence-free survival, distant metastasis-free survival, immunotherapy, targeted therapy, clinical trials
Takeaways
Keynote 716 focuses on adjuvant treatment for stage 2 melanoma.
The trial shows benefit for pembrolizumab in stage 2B and 2C.
There are challenges in treating early-stage melanoma effectively.
The hazard ratio for pembrolizumab is around 0.6 for stage 2.
Accurate biomarkers are needed for early-stage melanoma.
The majority of melanoma patients are diagnosed at stage 1 or 2.
Local and regional recurrences are concerning for patients.
The conversation around treatment options continues to evolve.
Titles
Keynote 716: A New Era for Stage 2 Melanoma
The Challenges of Treating Early-Stage Melanoma
Sound Bites
"This is basically adjuvant treatment for stage 2 melanoma."
"Keynote 716 was a randomized phase three trial."
"DMFS is really our most relevant endpoint for adjuvant trials."
Chapters
00:00 Introduction
02:38 Quickfire Questions and Introduction to Keynote 716
04:31 Keynote 716 Trial Design and Results
06:41 Interpreting DMFS and Regional Recurrence
08:40 Overlap Between Stage Two and Stage Three
10:58 Exploring Combination Therapy for Recurrence
13:15 Testing for BRAF Mutations in Stage Two
17:00 Reimbursement and Timing of Mutational Testing
22:18 Reimbursement Issues and Quick Results for Mutational Testing
25:00 Summary and Closing Remarks
